化合物MYCi361 T12132

Product Introduction
Bioactivity


英文名: MYCi361

描述: MYCi361 (NUCC-0196361) 是一种 MYC 抑制剂，抑制肿瘤生长并增强 anti-PD1 免疫疗法，其与 MYC 结合的 Kd 为 3.2 μM。

动物实验: FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors.MYCi361 treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days

体外活性: MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1].

体内活性: MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 100 mg/mL (168.1 mM)


关键字: c-Myc | MYCi 361 | NUCC0196361 | MYCi361 | NUCC 0196361 | MYCi-361 | inhibit | Inhibitor | Myc

相关产品: Aaptamine | APTO-253 | 10074-G5 | Lusianthridin | VPC-70063 | Mycro 3 | MDEG-541 | Moracin T | Nicotinamide N-oxide | Trachelogenin

相关库: Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Metabolism Compound Library | Cell Cycle Compound Library | Transcription Factor-Targeted Compound Library | Glutamine Metabolism Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Active Compound Library | Glycolysis Compound Library | NO PAINS Compound Library

化合物MYCi361 T12132信息由TargetMol中国为您提供，如您想了解更多关于化合物MYCi361 T12132报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途